Published in Drug Week, April 23rd, 2004
The study results showed that the formulation of oral cladribine, which has been developed by Serono and IVAX has met the targets for an orally administered product, with blood levels of cladribine in the expected therapeutic range. Efficacy studies of oral cladribine in MS patients are planned to start late 2004.
Previous phase II and phase III clinical trials have demonstrated the positive effect of injectable cladribine in patients with MS. In these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.